US Patent

US12213989 — Use of maribavir in treatment regimens

Method of Use · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2042-11-18 · 17y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using maribavir in treatment regimens.

USPTO Abstract

Characterization of drug-drug interaction properties and pharmacological properties of maribavir is useful to inform potential drug-drug interactions and dosing strategies when administering with co-medications.

Drugs covered by this patent

Livtencity (MARIBAVIR) · Takeda

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4137`	—	Livtencity

Patent Metadata

Patent number: US12213989
Jurisdiction: US
Classification: Method of Use
Expires: 2042-11-18
Drug substance claim: No
Drug product claim: No
Assignee: Takeda Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.